Bimabloc: Uses, Dosage & Side Effects

What Is Bimabloc and What Is It Used For?

Bimabloc belongs to a class of ophthalmic medications known as fixed-dose combination (FDC) eye drops, which combine two different active substances into a single formulation. The two active ingredients in Bimabloc are bimatoprost (0.3 mg/ml) and timolol (5 mg/ml, as timolol maleate). Each of these ingredients lowers intraocular pressure through a distinct pharmacological mechanism, and their combined effect is greater than either agent used alone. This additive benefit makes Bimabloc particularly valuable for patients whose elevated eye pressure cannot be adequately controlled with monotherapy.

Bimatoprost is a synthetic prostamide analogue that structurally resembles prostaglandin F2α. Unlike classical prostaglandin analogues such as latanoprost, which act primarily on the prostaglandin FP receptor, bimatoprost acts through a distinct prostamide pathway. Its primary mechanism of action involves increasing the outflow of aqueous humour — the clear fluid that fills the front portion of the eye — through both the uveoscleral (non-conventional) pathway and the trabecular meshwork (conventional pathway). By enhancing drainage through these dual routes, bimatoprost achieves potent and sustained reductions in intraocular pressure. Bimatoprost begins to lower IOP within approximately 4 hours of topical application, reaches its peak effect at around 8–12 hours, and maintains a clinically meaningful pressure-lowering effect for at least 24 hours, supporting once-daily dosing.

Timolol is a non-selective beta-adrenergic receptor blocking agent (beta-blocker) that has been used in ophthalmology for over four decades and remains one of the most widely prescribed topical glaucoma medications worldwide. Timolol reduces intraocular pressure by decreasing the production of aqueous humour by the ciliary body epithelium. It achieves this by blocking beta-2 adrenergic receptors on the ciliary epithelial cells, which are involved in the active secretion of aqueous humour. The onset of IOP reduction following timolol administration occurs within 30 minutes, with peak effect at approximately 1–2 hours. Although timolol also has some beta-1 blocking activity, it is the beta-2 receptor blockade that is primarily responsible for its IOP-lowering action in the eye.

The combination of these two agents provides complementary and additive IOP reduction. Bimatoprost increases aqueous outflow, while timolol decreases aqueous production. Clinical studies have demonstrated that the bimatoprost/timolol fixed combination achieves mean IOP reductions of 7–10 mmHg from baseline, which is approximately 30–40% from untreated levels. This is consistently greater than the reduction achieved by either bimatoprost or timolol alone. A large meta-analysis published in the British Journal of Ophthalmology confirmed that bimatoprost/timolol was among the most effective fixed-combination glaucoma therapies available, with IOP reductions comparable to or exceeding those of other prostaglandin/timolol combinations.

Bimabloc is indicated for the reduction of intraocular pressure in adult patients with two specific conditions:

• Open-angle glaucoma (OAG): A chronic, progressive optic neuropathy characterised by damage to the optic nerve head and gradual loss of peripheral vision. It is the most common form of glaucoma worldwide, affecting approximately 2–3% of the population over age 40. Elevated IOP is the most significant modifiable risk factor for OAG, and lowering IOP is the only proven treatment to slow disease progression.
• Ocular hypertension (OHT): A condition in which the intraocular pressure is consistently above the normal range (typically >21 mmHg) but without detectable damage to the optic nerve or visual field loss. Patients with OHT are at increased risk of developing glaucoma, and treatment with IOP-lowering medication can reduce this risk by approximately 50%, as demonstrated by the landmark Ocular Hypertension Treatment Study (OHTS).

Bimabloc is typically prescribed for patients who have insufficient IOP response to topical beta-blocker monotherapy or prostaglandin analogue monotherapy, or as replacement therapy in patients already receiving bimatoprost and timolol as separate eye drops, in whom these two agents have provided adequate IOP control. Consolidating two separate medications into a single drop offers several practical advantages: it simplifies the treatment regimen, improves adherence (a critical factor in glaucoma management, where poor compliance is a leading cause of disease progression), reduces the total preservative exposure to the ocular surface, and eliminates the need for a 5-minute waiting period between different eye drops.

What Should You Know Before Taking Bimabloc?

Contraindications

Bimabloc must not be used by patients with any of the following conditions. These contraindications arise primarily from the systemic beta-blocking properties of the timolol component, which can affect the heart, lungs, and circulatory system even when applied topically to the eye:

• Reactive airway disease including bronchial asthma (or a history of bronchial asthma): Timolol can cause bronchospasm by blocking beta-2 adrenergic receptors in the airways. Even topical ocular application can deliver sufficient systemic timolol to trigger severe bronchospasm in susceptible individuals. There have been reports of fatal asthma attacks in patients using ophthalmic beta-blockers.
• Severe chronic obstructive pulmonary disease (COPD): For the same reason, patients with severe COPD are at risk of airway obstruction from the beta-blocking effects of timolol.
• Sinus bradycardia: Timolol can slow the heart rate further in patients who already have a slow resting heart rate (below 60 beats per minute), potentially leading to symptomatic bradycardia or cardiac arrest.
• Second or third degree atrioventricular (AV) block not controlled with a pacemaker: Beta-blockers can worsen conduction abnormalities in the heart.
• Overt cardiac failure or cardiogenic shock: Timolol can depress myocardial contractility and worsen heart failure symptoms.
• Hypersensitivity to bimatoprost, timolol, other beta-adrenergic blocking agents, or any of the excipients in the formulation.

Warnings and Precautions

Before starting Bimabloc, inform your doctor about all of your medical conditions, particularly:

• Heart conditions: Coronary artery disease, Prinzmetal angina, mild heart failure, peripheral circulatory disorders (Raynaud phenomenon), or history of low blood pressure. Timolol can reduce heart rate, lower blood pressure, and mask signs of hypoglycaemia and thyrotoxicosis.
• Diabetes mellitus: Beta-blockers can mask the warning signs of acute hypoglycaemia (low blood sugar), particularly tachycardia and tremor. Patients with diabetes, especially those on insulin, should be advised that the symptoms of hypoglycaemia may be altered.
• Thyroid disorders: Timolol may mask certain signs of hyperthyroidism (overactive thyroid). Abrupt withdrawal may precipitate a thyroid storm.
• Corneal diseases: Ophthalmic beta-blockers may induce dry eye. Patients with corneal diseases should be treated with caution.
• History of atopy or severe anaphylactic reactions: Beta-blockers may enhance the response to allergens and make adrenaline (epinephrine) less effective in treating anaphylaxis.
• Myasthenia gravis: Beta-blockers may worsen muscle weakness.
• Hepatic impairment: Bimatoprost has not been extensively studied in patients with moderate to severe liver disease.

Important Eye-Related Effects

Before starting Bimabloc, your doctor should inform you about several potential ocular effects that are unique to prostaglandin analogue therapy:

• Iris colour change: Bimatoprost may gradually increase the amount of brown pigment in the iris (the coloured part of the eye). This effect is due to increased melanogenesis (production of melanin) in the iris melanocytes. The change is most noticeable in patients with mixed-colour irises (e.g., blue-brown, grey-brown, yellow-brown, or green-brown) and may be permanent. If only one eye is treated, a permanent difference in eye colour between the two eyes (heterochromia) may develop. The long-term consequences of increased iris pigmentation are not fully known.
• Periorbital changes: Bimatoprost can cause changes around the eye including deepening of the upper eyelid sulcus (the groove above the eyelid), darkening of the eyelid skin, and reduction of periorbital fat. These effects are usually reversible after treatment is discontinued.
• Eyelash changes: Bimatoprost can cause increased growth, thickness, pigmentation (darkness), and length of eyelashes. These changes may be unilateral if only one eye is treated. The changes are generally reversible when treatment is stopped.
• Macular oedema: Cystoid macular oedema has been reported with prostaglandin analogues, particularly in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular oedema. Bimabloc should be used with caution in these patients.

Pregnancy and Breastfeeding

There are limited data on the use of bimatoprost/timolol in pregnant women. Animal studies with bimatoprost have shown reproductive toxicity at high systemic exposures significantly above those reached by topical ophthalmic use. Timolol has been associated with foetal growth retardation when given by the oral or intravenous route at much higher doses than those absorbed from eye drops. However, as a precaution, Bimabloc should not be used during pregnancy unless clearly necessary and the potential benefit justifies the potential risk to the foetus. Women of childbearing potential should use effective contraception during treatment.

Timolol is excreted in human breast milk. It is not known whether bimatoprost is excreted in human milk, but animal studies have detected bimatoprost in breast milk. A decision must be made whether to discontinue breastfeeding or to discontinue Bimabloc therapy, taking into account the importance of the treatment to the mother. If treatment is necessary, breastfeeding is not recommended.

Contact Lens Use

Bimabloc contains benzalkonium chloride, a preservative commonly used in ophthalmic solutions. Benzalkonium chloride is known to discolour soft contact lenses and can be absorbed by them, potentially causing eye irritation. Patients who wear soft contact lenses should remove them before applying Bimabloc and wait at least 15 minutes after instillation before reinserting their lenses. Patients should be informed that benzalkonium chloride has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy with prolonged use, and the ocular surface should be monitored in patients who use preserved eye drops frequently or for extended periods.

How Does Bimabloc Interact with Other Drugs?

Drug interactions with Bimabloc are primarily related to the timolol component, which is absorbed systemically following topical ocular administration. Although the amount of timolol absorbed into the bloodstream from eye drops is relatively small, it can still exert clinically significant systemic beta-blocking effects, particularly in patients who are also taking oral medications that affect cardiovascular function. Nasolacrimal occlusion (pressing on the inner corner of the eye after applying the drops) is recommended to reduce systemic absorption and minimise the risk of drug interactions.

No formal drug interaction studies have been performed specifically with the bimatoprost/timolol fixed combination. However, based on the known pharmacology of each component and clinical experience, the following interactions should be considered:

When using multiple eye drops, allow at least 5 minutes between each medication to prevent dilution and washout of the first drop. If you are using another eye drop or eye ointment, Bimabloc should generally be applied last. If using an eye ointment, apply Bimabloc first and wait at least 5 minutes before applying the ointment.

It is important to note that even though timolol is applied topically to the eye, measurable blood levels do occur. Studies have shown that ophthalmic timolol 0.5% can achieve systemic concentrations comparable to a low oral dose, which is sufficient to produce clinically relevant cardiac and pulmonary effects. This underscores the importance of reporting all your medications, including eye drops, to every healthcare provider you see, not just your ophthalmologist.

What Is the Correct Dosage of Bimabloc?

Bimabloc should always be used exactly as your doctor has instructed. The standard dosage regimen is straightforward and designed to maximise both efficacy and adherence. Unlike some glaucoma medications that require twice-daily dosing, Bimabloc needs to be applied only once daily, which has been shown in clinical studies to improve patient compliance and treatment outcomes.

Adults (Including Elderly Patients)

The evening dosing is recommended because bimatoprost achieves its peak IOP-lowering effect approximately 8–12 hours after application. Since IOP tends to be highest in the early morning hours, evening administration ensures optimal pressure control during the critical nocturnal and early morning period. Additionally, some patients experience transient mild eye redness after applying prostaglandin analogues, which is less noticeable if the drop is given at bedtime.

To apply Bimabloc correctly and minimise systemic absorption, follow these steps:

1. Wash your hands thoroughly before handling the eye drop bottle.
2. Tilt your head back slightly and look upward.
3. Gently pull down the lower eyelid to create a small pocket (conjunctival sac).
4. Hold the bottle upside down close to your eye, without touching the eye or eyelid with the dropper tip.
5. Squeeze one drop into the lower eyelid pocket.
6. Close your eye gently (do not squeeze it shut) and press a finger against the inner corner of the eye (nasolacrimal duct) for 1–2 minutes. This nasolacrimal occlusion technique significantly reduces systemic absorption of both bimatoprost and timolol, decreasing the risk of cardiovascular and respiratory side effects.
7. Wipe away any excess solution from the skin around the eye. This is particularly important with bimatoprost-containing preparations to reduce the risk of periorbital skin darkening and increased eyelash growth in areas of skin contact.

If you wear contact lenses, remove them before applying the drops and wait at least 15 minutes before reinserting them.

Children and Adolescents

The safety and efficacy of Bimabloc have not been established in children and adolescents under 18 years of age. Bimabloc is not recommended for use in this population. Paediatric glaucoma requires specialised management, and treatment should be guided by a paediatric ophthalmologist using medications with established safety profiles in children.

Renal and Hepatic Impairment

No dose adjustment is necessary for patients with mild to moderate kidney (renal) impairment, as both bimatoprost and timolol undergo limited renal clearance following topical ocular administration. The pharmacokinetics of Bimabloc have not been specifically studied in patients with severe renal impairment or dialysis. Bimatoprost has not been extensively studied in patients with moderate to severe hepatic (liver) impairment, and caution is advised. Timolol is partially metabolised by the liver, and liver disease could theoretically increase systemic timolol levels, but clinically significant effects have not been documented with topical ophthalmic use.

Missed Dose

If you forget to apply Bimabloc at your usual time, apply it as soon as you remember, provided it is still the same day. If it is already the next day, skip the missed dose entirely and apply your next dose at the usual time the following evening. Do not apply a double dose to make up for a missed application, as this will not provide additional benefit and may increase the risk of side effects. Consistent, regular use is important for maintaining stable intraocular pressure control. Setting a daily alarm or using a medication reminder app can help you remember to use your eye drops at the same time each day.

Overdose

Topical overdose with Bimabloc is unlikely to cause serious systemic effects due to the small volume of medication applied. If an excess of drops is accidentally applied to the eye, rinse the eye with clean lukewarm water. If Bimabloc is accidentally ingested, symptoms are likely to be related to the timolol component and may include bradycardia (slow heart rate), hypotension (low blood pressure), bronchospasm, and cardiac failure. Treatment should be supportive: atropine for bradycardia, isoprenaline for bronchospasm, and inotropic agents (such as dobutamine) for heart failure. Haemodialysis is not effective for removing timolol. In cases of accidental ingestion, contact your local poison control centre or seek emergency medical attention.

What Are the Side Effects of Bimabloc?

Like all medicines, Bimabloc can cause side effects, although not everybody gets them. Most side effects are localised to the eye and surrounding tissues and are mild to moderate in severity. However, because timolol is absorbed into the bloodstream following ocular application, systemic side effects affecting the heart, lungs, and nervous system can occur, albeit uncommonly. The side effects listed below reflect the combined safety profiles of both bimatoprost and timolol from clinical trials and post-marketing surveillance.

The frequency categories used below follow the international convention: very common (may affect more than 1 in 10 people), common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people), and rare (may affect up to 1 in 1,000 people).

The most characteristic side effect of bimatoprost — and one that distinguishes prostaglandin analogues from all other glaucoma medications — is the potential for permanent iris colour change. This results from an increase in melanin content within the iris stromal melanocytes, not from an increase in the number of melanocytes. The change occurs gradually over months to years and is most apparent in eyes with mixed-colour irises. In clinical trials, iris colour change was reported in approximately 0.5–1% of patients per year, but the true incidence may be higher with long-term use. Your ophthalmologist should photograph your iris at baseline and monitor for colour changes at regular intervals.

If you notice any side effects, particularly shortness of breath, chest tightness, unusual tiredness, swelling, or changes in heart rhythm, stop using the eye drops and contact your doctor immediately. For most ocular side effects (mild redness, transient stinging), these tend to diminish over the first few weeks of treatment as your eyes adapt to the medication.

How Should You Store Bimabloc?

Proper storage of Bimabloc is essential to maintain the sterility, stability, and efficacy of the eye drops throughout their use. Eye drops are particularly sensitive to contamination, temperature fluctuations, and light exposure, and improper storage can lead to reduced effectiveness or even introduce harmful microorganisms into the eye.

Follow these storage guidelines carefully:

• Before opening: Store at a temperature below 30°C. Do not refrigerate or freeze. Keep the bottle in the outer carton to protect it from light.
• After opening: Use the eye drops within 28 days of first opening the bottle. This is because the preservative system (benzalkonium chloride) provides antimicrobial protection for a limited period once the bottle seal is broken and the solution is exposed to air and potential contamination from repeated use.
• Do not freeze: Freezing can damage the formulation and alter the concentration of active ingredients.
• Do not use after the expiry date: The expiry date refers to the last day of that month and is printed on the bottle label and outer carton.
• Keep out of sight and reach of children: Accidental ingestion of beta-blocker eye drops by children can cause serious cardiovascular effects.
• Cap tightly after use: Always replace the cap securely after each use to prevent contamination and evaporation.
• Do not share: Never share your eye drops with another person, even if they have the same condition, as this risks cross-contamination and infection.

Dispose of any unused eye drops 28 days after opening, even if there is solution remaining in the bottle. It can be helpful to write the date of opening on the label or outer carton. Do not dispose of medicines via wastewater or household waste. Return unused or expired medication to your pharmacy for safe disposal in accordance with local regulations.

What Does Bimabloc Contain?

Understanding the full composition of Bimabloc is important, particularly for patients with known allergies or sensitivities to specific pharmaceutical ingredients. The formulation consists of two categories of ingredients: the active substances that provide the therapeutic effect, and the excipients (inactive ingredients) that serve as the vehicle, preservative, and stabiliser for the solution.

Active Ingredients

Excipients (Inactive Ingredients)

The inactive ingredients in Bimabloc serve essential pharmaceutical functions:

• Benzalkonium chloride (0.05 mg/ml): Acts as a preservative to maintain sterility of the multi-dose bottle. Benzalkonium chloride is a quaternary ammonium compound with broad-spectrum antimicrobial activity. It is the most widely used preservative in ophthalmic solutions but can cause ocular surface toxicity with long-term use, particularly in patients with dry eye disease.
• Sodium chloride: Provides tonicity adjustment to make the solution isotonic with tears, ensuring comfort upon application and preventing osmotic damage to corneal epithelial cells.
• Disodium hydrogen phosphate: Functions as a buffering agent to maintain the pH of the solution within an acceptable range for ocular administration (typically pH 6.9–7.5).
• Citric acid monohydrate: Also functions as a buffering agent and chelating agent, contributing to the stability of the formulation.
• Hydrochloric acid or sodium hydroxide: Used during manufacturing to adjust the pH of the solution to the optimal range.
• Purified water: The primary vehicle for the active ingredients and excipients.

The solution is clear, colourless to slightly yellow. Each bottle typically contains 3 ml of solution. Inspect the solution before each use; do not use if the solution appears cloudy, discoloured, or contains visible particles. If the dropper tip becomes contaminated by touching any surface (including the eye), the risk of microbial contamination increases; contact your pharmacist for advice on whether the bottle should be replaced.